VTv Therapeutics Story

<div class='circular--portrait' style='background:#689CFD;color: #ffffff;font-size:4em;'>VT</div>
VTVT -- USA Stock  

USD 2.13  0.03  1.39%

VTv Therapeutics Net Cash Flow or Change in Cash and Cash Equivalents is comparatively stable at the moment as compared to the past year. VTv Therapeutics reported Net Cash Flow or Change in Cash and Cash Equivalents of 77.96 Million in 2019. Issuance Repayment of Debt Securities is likely to gain to about 29.3 M in 2020, whereas Earnings Before Interest Taxes and Depreciation Amortization EBITDA are likely to drop (21.6 M) in 2020. As many baby boomers are still indifferent towards healthcare space, it makes sense to review vTv Therapeutics. We will evaluate if VTv Therapeutics shares are reasonably priced going into January. Here I will also expose some primary fundamental factors affecting VTv Therapeutics' services, and outline how it will impact the outlook for investors this year.
Published over a month ago
View all stories for VTv Therapeutics | View All Stories
What are the odds of VTv Therapeutics to drop in January?
VTv Therapeutics reported the previous year's revenue of 22 K. Net Loss for the year was (14.66 M) with loss before overhead, payroll, taxes, and interest of (12.36 M).

How important is VTv Therapeutics's Liquidity

VTv Therapeutics financial leverage refers to using borrowed capital as a funding source to finance vTv Therapeutics ongoing operations. It is usually used to expand the firm's asset base and generate returns on borrowed capital. VTv Therapeutics financial leverage is typically calculated by taking the company's all interest-bearing debt and dividing it by total capital. So the higher the debt-to-capital ratio (i.e., financial leverage), the riskier the company. Please check the breakdown between VTv Therapeutics's total debt and its cash.

How VTv Therapeutics utilizes its cash?

To perform a cash flow analysis of VTv Therapeutics, investors first need to understand how to read the cash flow statement. A cash flow statement shows the amount of cash VTv Therapeutics is receiving and how much cash it distributes out in a given period. The VTv Therapeutics cash flow statement breaks down these inflows and outflows into different buckets, including operating activities, investing activities, and financing activities. VTv Therapeutics Net Cash Flow from Operations is comparatively stable at the moment as compared to the past year. VTv Therapeutics reported Net Cash Flow from Operations of (20.72 Million) in 2020

Detailed Perspective On VTv Therapeutics

VTv Therapeutics maintains a total of 51.84 Million outstanding shares. vTv Therapeutics has majority of its outstanding shares owned by insiders. An insider is usually defined as a corporate executive, director, member of the board or institutional investor who own at least 10% of the company outstanding shares. 69.92 % of VTv Therapeutics outstanding shares that are owned by insiders indicates they have been buying or selling the stock in recent months in anticipation of some upcoming event. Remember, it does not matter who owns the company or if the company is currently losing money. If the true value of the company is more than the market pays for it currently, you can still have a good investment opportunity.

Ownership Breakdown

Retail Investors
Retail Investors21.78

VTv Therapeutics showing indication of lower volatility

VTv Therapeutics newest skewness boosts over 0.92. vTv Therapeutics shows above-average downside volatility for the selected time horizon. We advise investors to inspect vTv Therapeutics further and ensure that all market timing and asset allocation strategies are consistent with the estimation of VTv Therapeutics future alpha.

Our Conclusion on VTv Therapeutics

Whereas some other companies within the biotechnology industry are still a little expensive, even after the recent corrections, VTv Therapeutics may offer a potential longer-term growth to private investors. Taking everything into account, as of the 11th of December 2020, our analysis shows that VTv Therapeutics moves indifferently to market moves. The firm is undervalued and projects very small probability of bankruptcy for the next 2 years. However, our primary 30 days 'Buy-vs-Sell' recommendation on the firm is Strong Sell.

About Contributor

This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Raphi Shpitalnik do not own shares of vTv Therapeutics. Please refer to our Terms of Use for any information regarding our disclosure principles.

Would you like to provide feedback on the content of this article?

You can get in touch with us directly or send us a quick note via email to editors@macroaxis.com